Camrelizumab (anti-PD-1 inhibitor) Clinical Trials
2 recruitingDrug
Phase 22
Showing 1–2 of 2 trials
Recruiting
Phase 2
Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment
Hepatocellulcar Carcinoma
Sun Yat-sen University30 enrolled1 locationNCT07238881
Recruiting
Phase 2
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
Oral Squamous Cell CarcinomaNeoadjvant TherapyAnti-PD-1+1 more
Shanghai Jiao Tong University School of Medicine46 enrolled1 locationNCT05069857